A7i has corrected a figure, previously carried on this site, stating that the Emirati Genome Programme had sequenced more than 800,000 samples. The correction is instructive about how genomics numbers travel.
M42, which runs the programme, states that 780,000 UAE nationals took part in it. Taking part is enrolment: consenting, giving a sample, answering a questionnaire. The operator describes the figure as participation, a distinct measure from completed whole-genome sequencing. Separately, the largest published analysis from the programme, a September 2025 preprint, reports genetic insights from 43,608 individuals.
Those two numbers are both accurate and they measure different things. The distance between them, better than an order of magnitude, is where the translation opportunity sits.
Qatar is smaller and more consolidated
The Qatar Precision Health Institute consolidates the Qatar Biobank, established in 2012, and the Qatar Genome Programme, launched in 2015. It describes recruitment of nearly 50,000 participants, a figure closer in scale to the Emirati published-analysis cohort than to the Emirati enrolment.
Qatar's structure is also different. Both programmes sit inside Qatar Foundation alongside Sidra Medicine and the Qatar Biomedical Research Institute, which means the dataset, the clinical site and the research base share an owner. In Abu Dhabi the equivalent capability is distributed across the Department of Health, M42, PureHealth and a series of commercial partners.
The consanguinity advantage is real, and the next layer decides its value
High consanguinity concentrates rare inherited disease in Gulf populations, which makes these datasets scientifically valuable in a way that sets them apart from larger Western biobanks. This is the most frequently cited argument for the region's genomics position and it is correct.
The open question is who captures the value. A dataset that is unusually informative about rare disease is an input to drug development. Whether the region's programmes become the basis for therapies owned in the Gulf, or a recruitment and discovery resource that others build on, depends on the layer above them, and building that layer is the region's next opportunity.
The first programme doing clinical work
The Alzheimer's prevention trial launched in Abu Dhabi in June 2026 uses Emirati Genome Programme data to identify APOE4 carriers before symptom onset and then trials an investigational therapy in that cohort. This is the first published instance of a Gulf population dataset constructing a trial rather than describing a population.
The therapeutic asset is American. The dataset and the recruitment strategy are Emirati. That division of labour is the current shape of Gulf genomics, and stating it plainly shows where the next domestic step lies: a Gulf-owned asset trialled on Gulf data.